MIF1 and MIF2 Myostatin Peptide Inhibitors as Potent Muscle Mass Regulators

The use of peptides as drugs has progressed over time and continues to evolve as treatment paradigms change and new drugs are developed. Myostatin (MSTN) inhibition therapy has shown great promise for the treatment of muscle wasting diseases. Here, we report the MSTN-derived novel peptides MIF1 (10-...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Eun Ju, Shaikh, Sibhghatulla, Baig, Mohammad Hassan, Park, So-Young, Lim, Jeong Ho, Ahmad, Syed Sayeed, Ali, Shahid, Ahmad, Khurshid, Choi, Inho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031736/
https://www.ncbi.nlm.nih.gov/pubmed/35457038
http://dx.doi.org/10.3390/ijms23084222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031736/
https://www.ncbi.nlm.nih.gov/pubmed/35457038
http://dx.doi.org/10.3390/ijms23084222

Ejemplares similares